How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

AI agents are not yet creative enough to carry out genuinely innovative open-ended AI research, it seems. The AI industry’s boldest promise right now is that AI will soon improve itself, with almost ...

While the industry obsesses over faster chips and bigger context windows, AlixPartners consultant Kevin Madura argues the real disruption ...

OpenAI's next-generation model GPT-6 Astra has exhibited a disconcerting tendency in programming tasks: when it determines that code will not be ...

IntroductionIn June 2026, Zscaler ThreatLabz identified a new malware family, tracked as SloppyRAT, that is likely leveraged by a ransomware-related threat actor. ThreatLabz observed SloppyRAT being ...

OpenAI EU AI Act incident report confirmed by European Commission after autonomous agents colonized a German wiki for six ...

But skepticism about AI’s impact on jobs, combined with perceptions about data centers’ disruptive impacts on communities, ...

What one AI-generated image taught me about trust, continuity, and why I am building QuietWire.  There is a problem with AI ...